Articoli
A, et al. Differential effectiveness of selected non‐psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Exp Dermatol. 2016 Sep;25(9):701-7. doi: 10.1111/exd.13042.
Acesso: link
Abels C, Soeberdt M. Can we teach old drugs new tricks? Repurposing of neuropharmacological drugs for inflammatory skin diseases. Exp Dermatol. 2019 Sep;28(9):1002-1009. doi: 10.1111/exd.13987.
Acesso: link
Kircik LH. What’s new in the management of acne vulgaris. Cutis. 2019 Jul;104(1):48-52. Review.
Acesso: link
Sheriff T, et al. The potential role of cannabinoids in dermatology. J Dermatolog Treat. 2019 Oct 10:1-7. doi: 10.1080/09546634.2019.1675854.
Acesso: link
Cohen PR. Therapeutic and cosmetic uses of Cannabis: Cannabinoids for acne treatment and skin rejuvenation. Skinmed 2021; 19(1):45-47.
Acesso: link
Nickles MA, Lio PA. Cannabinoids in dermatology: hope or hype? Cannabis Cannabinoid Res 2020; 5(4):279-282.
Acesso: link
Baswan SM, et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin Cosmet Investig Dermatol. 2020; 13:927-942. doi: 10.2147/CCID.S286411.
Acesso: link
Stella F, et al. Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: systematic review. Trends Psychiatry Psychother. 2021 Jul 20. doi: 10.47626/2237-6089-2021-0288.
Acesso: link
Brucki SMD, et al. Cannabinois in neurology – Brazilian Academy of Neurology. Arq Neuro-Psiquiatr 2015; 73(4):371-374.
Acesso: link
Antonsdottir IM, et al. Dazed and Confused: Medical Cannabis in Alzheimer Disease. Am J Geriatr Psychiatry. 2016 Nov;24(11):1004-1006. doi: 10.1016/j.jagp.2016.08.015. Epub 2016 Aug 31.
Acesso pago: link
Russo EB. Cannabis Therapeutics and the Future of Neurology. Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018.
Acesso: link
Cristino L, et al. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020 Jan;16(1):9-29. doi: 10.1038/s41582-019-0284-z. Epub 2019 Dec 12.
Acesso: link
Peprah K, McCormack S. Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.
Acesso: link
Vallée A, et al. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim Biophys Sin (Shanghai). 2017 Oct 1;49(10):853-866. doi: 10.1093/abbs/gmx073.
Acesso: link
Solimini R, et al. Neurological Disorders in Medical Use of Cannabis: An Update. CNS Neurol Disord
Drug Targets. 2017; 16(5):527-533. doi: 10.2174/1871527316666170413105421.
Acesso: link
Aso E, et al. Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model. J Alzheimers Dis. 2016 Oct 4;54(3):903-912.
Acesso: link
Ahmed A, et al. Cannabinoids in late-onset Alzheimer’s disease. Clin Pharmacol Ther. 2015 Jun;97(6):597-606. doi: 10.1002/cpt.117.
Acesso: link
Cooray R, et al. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Mol Neurobiol. 2020 Aug 19. doi: 10.1007/s12035-020-02054-6.
Acesso: link
Ożarowski M, et al. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. International Journal of Molecular Sciences. 2021; 22(9):4294.
Acesso: link
Abate G, et al. Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy. Biology (Basel). 2021; 10(6):542.
Acesso: link
Monteiro KLC, et al. Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease. Neural Regen Res. 2021;16(5):990-991.
Acesso: link
Gopalakrishna G, et al. Cannabinoids in the management of frontotemporal dementia: a case series. Neurodegener Dis Manag. 2021; 11(1):61-64.
Acesso: link
Zuardi AW, et al. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993; 7:82–88. doi: 10.1177/026988119300700112.
Acesso: link
Zuardi AW, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9−THC in normal subjects. Psychopharmacol 1982; 76:245−250, 1982.
Acesso: link
Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J. Psychopharmacol 2011; 25:121–130. doi: 10.1177/0269881110379283.
Acesso: link
Zuari A, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017; 8:259
Acesso: link
Linares et al. Cannabidiol presents an inverted U-shaped dose-response curve in a
simulated public speaking test . Braz J Psychiatry. 2019; 41(1):9-14
Acesso: link
Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. doi: 10.7812/TPP/18-041.
Acesso: link
Chadwick V, et al. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Curr Opin Psychiatry. 2020 Jan;33(1):20-42. doi: 10.1097/YCO.0000000000000562.
Acesso: link
Skelley, J., Deas, C., Curren, Z., Ennis, J. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). Jan-Feb 2020;60(1):253-261.
Acesso: link
Petrie GN, et al. Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology. 2021; 195:108626. doi: 10.1016/j.neuropharm.2021.108626.
Acesso: link
Renslo B, Greis A, Liu CS, Radakrishnan A, Ilyas AM. Medical Cannabis Use Reduces Opioid Prescriptions in Patients With Osteoarthritis. Cureus. 2022 Jan 24;14(1):e21564. doi: 10.7759/cureus.21564.
Acesso: link
Blake DR, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45(1):50–2.
Acesso: link
Richardson D, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R43. doi: 10.1186/ar2401. Epub 2008 Apr 16. PMID: 18416822; PMCID: PMC2453762.
Acesso: link
Sido JM, et al. Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease. Int Rev Immunol. 2015;34(5):403-14. doi: 10.3109/08830185.2014.921165. Epub 2014 Jun 9. PMID: 24911431; PMCID: PMC4261058.
Acesso: link
Lowin T, Straub RH. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res Ther. 2015 Sep 6;17(1):226. doi: 10.1186/s13075-015-0743-x. PMID: 26343051; PMCID: PMC4561168.
Acesso: link
Gui H, et al. The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. Int Immunopharmacol. 2015 May;26(1):86-91. doi: 10.1016/j.intimp.2015.03.006. Epub 2015 Mar 16. PMID: 25791728.
Acesso: link
Barrie N, et al. Endocannabinoids in arthritis: current views and perspective. Int J Rheum Dis. 2017 Jul;20(7):789-797. doi: 10.1111/1756-185X.13146. PMID: 28736968.
Acesso: link
Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi: 10.5152/eurjrheum.2017.17025. Epub 2017 Sep 1. PMID: 29164003; PMCID: PMC5685274.
Acesso: link
Lowin T, et al. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020 Sep 1;11(8):714. doi: 10.1038/s41419-020-02892-1. PMID: 32873774; PMCID: PMC7463000.
Acesso: link
Kaur I, et al. The endocannabinoid signaling pathway as an emerging target in pharmacotherapy, earmarking mitigation of destructive events in rheumatoid arthritis. Life Sci. 2020 Sep 15;257:118109. doi: 10.1016/j.lfs.2020.118109. Epub 2020 Jul 19. PMID: 32698072.
Acesso: link
Sarzi-Puttini P, et al. Cannabinoids in the treatment of rheumatic diseases: Pros and cons. Autoimmun Rev. 2019 Dec;18(12):102409. doi: 10.1016/j.autrev.2019.102409. Epub 2019 Oct 21. PMID: 31648042.
Acesso: link
Prieto González JM, Vila Silván C. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years’ accumulated evidence from clinical trials. Expert Rev Neurother. 2021. doi: 10.1080/14737175.2021.1935879.
Acesso: link
Bryk M, Starowicz K. Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review. Pharmacol Rep. 2021; 73(3):681-699. doi: 10.1007/s43440-021-00270-y.
Acesso: link
Schulze-Schiappacasse C, et al. Are Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids a Therapeutic Tool for Rheumatoid Arthritis? A Friendly Summary of the Body of Evidence. J Clin Rheumatol. 2021. doi: 10.1097/RHU.0000000000001745.
Acesso: link
Costa JLGP, et al. Neurobiology of Cannabis: from the endocannabinoid system to cannabis-related disorders. J Bras Psiquiatr 2011; 60(2).
Acesso: link
Bar-Lev Schleider, et al. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Scientific Reports. 2019; 9(1):200
Acesso: link
Fusar-Poli, L., et al. Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. Brain Sci. 2020, 10, 572. doi: 10.3390/brainsci10090572.
Acesso: link
Silva EAD Junior, et al. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends Psychiatry Psychother. 2021. doi: 10.47626/2237-6089-2020-0149.
Acesso: link
Aran A, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021; 12(1):6. doi: 10.1186/s13229-021-00420-2.
Acesso: link
Nezgovorova V, et al. Potential of cannabinoids as treatments for autism spectrum disorders. J Psychiatr Res. 2021; 137:194-201. doi: 10.1016/j.jpsychires.2021.02.048.
Acesso: link
Fleury-Teixeira P, et al. Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use. Front Neurol. 2019; 10:1145. doi: 10.3389/fneur.2019.01145.
Acesso: link
Crippa JAS, et al. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open 2021; 4(8):e2120603. doi: 10.1001/jamanetworkopen.2021.20603.
Acesso: link
Nguyen LC, et al. Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response. bioRxiv [Preprint]. 2021 Mar 10:2021.03.10.432967. doi: 10.1101/2021.03.10.432967. PMID: 33758843; PMCID: PMC7987002.
Acesso: link
Brugliera L, et al. Therapeutic cannabis for pain management in a patient with chiari malformation type i during concomitant SARS-COV-2 infection. J Neurosurg Sci. 2021 Mar 11. doi: 10.23736/S0390-5616.21.05322-4. Epub ahead of print. PMID: 33709669.
Acesso: link
Malinowska B, et al. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19. Int J Mol Sci. 2021 Feb 17;22(4):1986. doi: 10.3390/ijms22041986. PMID: 33671463; PMCID: PMC7922403.
Acesso: link
O’Sullivan SE, et al. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders? Cannabis Cannabinoid Res. 2021 Feb 12;6(1):7-18. doi: 10.1089/can.2020.0102. PMID: 33614948; PMCID: PMC7891214.
Acesso: link
Land MH, et al. Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs. Cannabis Cannabinoid Res. 2020 Dec 15;5(4):340-343. doi: 10.1089/can.2020.0054. PMID: 33381648; PMCID: PMC7759270.
Acesso: link
Suryavanshi SV, et al. Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective. Front Immunol. 2021 Jan 28;11:613613. doi: 10.3389/fimmu.2020.613613. PMID: 33584697; PMCID: PMC7876066.
Acesso: link
Anil SM, et al. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep. 2021 Jan 14;11(1):1462. doi: 10.1038/s41598-021-81049-2. PMID: 33446817; PMCID: PMC7809280.
Acesso: link
Khalsa JH, et al. COVID-19 and Cannabidiol (CBD). J Addict Med. 2020 Dec 14. doi: 10.1097/ADM.0000000000000771. Epub ahead of print. PMID: 33323690.
Acesso: link
Khalid S, et al. Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A new Route to Fight against COVID-19? Curr Pharm Des. 2020 Dec 2. doi: 10.2174/1381612826666201202125807. Epub ahead of print. PMID: 33267756.
Acesso: link
Wang B, et al. In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY). 2020 Nov 22;12(22):22425-22444. doi: 10.18632/aging.202225. Epub 2020 Nov 22. PMID: 33221759; PMCID: PMC7746344.
Acesso: link
Onaivi ES, Sharma V. Cannabis for COVID-19: can cannabinoids quell the cytokine storm? Future Sci OA. 2020 Aug 13;6(8):FSO625. doi: 10.2144/fsoa-2020-0124. PMID: 32974048; PMCID: PMC7451410.
Acesso: link
Khodadadi H, et al. Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA. Cannabis Cannabinoid Res. 2020 Sep 2;5(3):197-201. doi: 10.1089/can.2020.0043. PMID: 32923657; PMCID: PMC7480719.
Acesso: link
Sainz-Cort A, Heeroma JH. The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection. J Cannabis Res. 2020;2(1):23. doi: 10.1186/s42238-020-00030-4. Epub 2020 Jul 31. PMID: 32835160; PMCID: PMC7393810.
Acesso: link
Esposito G, et al. The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 2020 Nov;177(21):4967-4970. doi: 10.1111/bph.15157. Epub 2020 Jul 16. PMID: 32519753; PMCID: PMC7300643.
Acesso: link
Pacheco JC, et al. Cannabidiol as a Treatment for Mental Health Outcomes Among Health Care Workers During the Coronavirus Disease Pandemic. J Clin Psychopharmacol. 2021; 41(3):327-329. doi: 10.1097/JCP.0000000000001405.
Acesso: link
O’Sullivan SE, et al. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders? Cannabis Cannabinoid Res. 2021; 6(1):7-18. doi: 10.1089/can.2020.0102.
Acesso: link
Howard I. Cannabis Hyperemesis Syndrome in Palliative Care: A Case Study and Narrative Review. J Palliat Med 2019; 22(10):1227-1231. doi: 10.1089/jpm.2018.0531.
Acesso: link
Wong DF, et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010; 4:1505Y1513.
Acesso: link
Wise RA. Dopamine reward: the anhedonia hypothesis 30 years on. Neurotox Res 2008; 14:169-83.
Acesso: link
Vandrey R, et al. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 2013; 128:64-70.
Acesso: link
Trigo JM &Le Foll B. Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine seeking behavior in mice. Psychopharmacology (Berl) 2016; 233(10):1815–22.
Acesso: link
Trigo JM, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PloS One 2018; 13:e0190768.
Acesso: link
Trigo JM, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend 2016; 161:298-306.
Acesso: link
Serrano A & Parsons LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 2011; 132(3):215–41.
Acesso: link
Schlienz DC, et al. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend 2018; 187:254-260.
Acesso: link
Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharm 2009; 32:269-76.
Acesso: link
Robinson JD et al. Pooled analysis of three randomized, double-blind, placebo-controlled trials with rimonabant for smoking cessation. Addiction Biol 2018; 23:291-303.
Acesso: link
Ren Y, et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cueinduced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009; 29(47):14764–9.
Acesso: link
Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci 2015; 16(10):579–94.
Acesso: link
Navarro G et al. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1–CB2 heteroreceptor complexes. Biochem Pharmacol 2018; 157:148–58.
Acesso: link
Morgan CJA et al. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013; 38:2433-2436.
Acesso: link
Manzanares J et al. Role of the endocannabinoid system in drug addiction. Biochem Pharmacol 2018; 157:108–21.
Acesso: link
Lundahl LH, Greenwald MK. Effect of oral THC pretreatment on marijuana cue-induced responses in cannabis dependent volunteers. Drug Alcohol Depend 2015; 149:187-193.
Acesso: link
Luján MÁ et al. Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus. Neuropharmacology 2018; 143:163–75.
Acesso: link
Lofwall MRet al. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend 2016; 164:143-150.
Acesso: link
Lintzeris N et al. Nabiximols for the treatment of cannabis dependence A randomized clinical trial. JAMA Intern Med 2019; 179:1242-1253.
Acesso: link
Levin FR et al. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011; 116:142-150.
Acesso: link
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 2016; 3(8):760-773.
Acesso: link
Jordan CJ, Xi ZX. Progress in brain cannabinoid CB2 receptor research: from genes to behavior. Neurosci Biobehav Rev 2019; 98:208–20.
Acesso: link
Hindocha C, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 2015; 25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014.
Acesso: link
Hill et al. Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addict 2017; 26:795-801.
Acesso: link
Hermanns−Clausen M, et al. 2013. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction.; 108(3):534−544.
Acesso: link
Galaj E et al. Cannabidiol attenuates the rewarding efects of cocaine by CB2, 5-TH1A and TRPV1 receptor mechanisms. Neuropharmacology 2020; 1;167:107740.
Acesso: link
Crippa JA, et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: A case report. J Clin Pharm Ther 2013; 38:162–164. doi: 10.1111/jcpt.12018.
Acesso: link
Bisaga A et al. The effects of dronabinol during detoxification and the initiation of treatment with extended-release naltrexone. Drug Alcohol Depend 2015; 154:38-45.
Acesso: link
Allsop DJ et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal. JAMA Psychiatr 2014; 71:281.
Acesso: link
Galaj E, Xi ZX. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. CNS Drugs. 2019 Oct;33(10):1001-1030. doi: 10.1007/s40263-019-00664-w.
Acesso pago: link
Lee JLC, et al. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol. 2017 Oct;174(19):3242-3256. doi: 10.1111/bph.13724. Epub 2017 Mar 9
Acesso: link
Elsaid S, Le Foll B. The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders. Neuropsychopharmacology. 2020 Jan;45(1):229-230. doi: 10.1038/s41386-019-0518-1.
Acesso: link
Freeman, T., et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 2020. DOI: link
Acesso:link
Hurd Y., et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019 Nov 1;176(11):911-922. doi: 10.1176/appi.ajp.2019.18101191. Epub 2019 May 21.
Acesso: link
Spanagel R. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues Clin Neurosci. 2020 Sep;22(3):241-250. doi: 10.31887/DCNS.2020.22.3/rspanagel. PMID: 33162767; PMCID: PMC7605022.
Acesso: link
Navarrete F, et al. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Front Pharmacol. 2021; 12:626010. doi: 10.3389/fphar.2021.626010.
Acesso: link
Zanelati TV, et al. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. 2010 Jan;159(1):122-8. doi: 10.1111/j.1476-5381.2009.00521.x. Epub 2009 Dec 4.
Acesso: link
Mannekote Thippaiah S, et al. Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors. Front Psychiatry. 2021; 12:636228. doi: 10.3389/fpsyt.2021.636228.
Acesso: link
García-Gutiérrez MS, et al. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules. 2020; 10(11):1575. doi: 10.3390/biom10111575.
Acesso: link
Murillo-Rodríguez E, et al. The Endocannabinoid System May Modulate Sleep Disorders In Aging. Curr Neuropharmacol. 2019 Aug 1. doi: 10.2174/1570159X17666190801155922. [Epub ahead of print]
Acesso: link
Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. doi: 10.7812/TPP/18-041.
Acesso: link
Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9.
Acesso pago: link
Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016 Fall;20(4):16-005. doi: 10.7812/TPP/16-005. Epub 2016 Oct 12
Acesso: link
Suraev, A., et al. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Med Rev. 2020 May 16;53:101339. doi: 10.1016/j.smrv.2020.101339. Online ahead of print.
Acesso: link
Suraev, A., et al. Cannabidiol (CBD) and Δ 9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open. 2020 May 18;10(5):e034421. doi: 10.1136/bmjopen-2019-034421.
Acesso: link
Walsh JH, et al. Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo. Sleep. 2021: zsab149. doi: 10.1093/sleep/zsab149.
Acesso: link
Murillo-Rodríguez E, et al. Natural Cannabinoids as Templates for Sleep Disturbances Treatments. Adv Exp Med Biol. 2021;1297:133-141. doi: 10.1007/978-3-030-61663-2_9.
Acesso: link
Few J, et al. A Single-Center Study Evaluating the Effects of a Novel Retinol and Cannabidiol Combination Topical on Facial Skin. Aesthet Surg J Open Forum. 2022 Jan 27;4:ojac002. doi: 10.1093/asjof/ojac002.
Acesso: link
Sivesind TE, et al. Cannabinoids for the Treatment of Dermatologic Conditions. JID Innov. 2022 Jan 13;2(2):100095.
Acesso: link
Junaid MSA, et al. In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils. Int J Pharm. 2022 Mar 25;616:121540. doi: 10.1016/j.ijpharm.2022.121540.
Acesso: link
Scheffer IE, et al. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA Netw Open. 2021 Sep 1;4(9):e2123930. doi: 10.1001/jamanetworkopen.2021.23930.
Acesso: link
Zouboulis CC, et al. What is the pathogenesis of acne? Exp Dermatol. 2005;14(2):143−52.
Acesso: link
van Zuuren EJ. Rosacea. N Engl J Med. 2017 Nov 2;377(18):1754−64.
Acesso: link
Stander S, et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J. Dermatol. Sci. 2005; 38, 177−88.
Acesso: link
Río CD, et al. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol 2018; 157:122−33. Review.
Acesso: link
Pucci M, et al. Endocannabinoid signaling and epidermal differentiation. Eur. J. Dermatol. 2011; 21(Suppl 2), 29−34.
Acesso: link
Oláh A, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713−24.
Acesso: link
Oláh A, et al. Differential effectiveness of selected non−psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Exp Dermatol. 2016 Sep;25(9):701−7.
Acesso: link
Oláh A, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713−24.
Acesso: link
Maida V e Corban J. Topical Medical Cannabis: A New Treatment for Wound Pain – Three Cases of Pyoderma Gangrenosum. J Pain Symptom Manage. 2017 Nov;54(5):732−6.
Acesso: link
Lodzki M, et al. Cannabidiol−transdermal delivery and anti−inflammatory effect in a murine model. J. Control. Release. 2003; 93:377−87.
Acesso: link
Kupczyk P, et al. Cannabinoid system in the skin − a possible target for future therapies in dermatology. Exp Dermatol. 2009;18(8):669−79.
Acesso: link
Hammell DC, et al. Transdermal cannabidiol reduces inflammation and pain−related behaviours in a rat model of arthritis. Eur J Pain. 2016 July; 20(6): 936−948.
Acesso: link
Gupta AK, Talukder M. Cannabinoids for skin diseases and hair regrowth. J Cosmet Dermatol. 2021 Sep;20(9):2703-2711. doi: 10.1111/jocd.14352.
Acesso: link
Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7(5):438−55.
Acesso: link
Caterina MJ. TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci 2014; 5(11):1107−16.
Acesso: link
Biro T, et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci 2009; 30, 411−20.
Acesso: link
Anand U, et al. Cannabinoid receptor CB2 localisation and agonist−mediated inhibition of capsaicin responses in human sensory neurons. Pain. 2008; 138, 667−80.
Acesso: link
Palmieri B , et al. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Clin Ter. 2019 Mar-Apr;170(2):e93-e99. doi: 10.7417/CT.2019.2116.
Acesso: link
Baswan SM, et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin Cosmet Investig Dermatol. 2020 Dec 8;13:927-942. doi: 10.2147/CCID.S286411. PMID: 33335413; PMCID: PMC7736837.
Acesso: link
Rietcheck HR, et al. Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson’s Disease and the Potential Role of Oral Cannabinoids. Dermatology 2020. doi: 10.1159/000512189
Acesso: link
Szachowicz-Petelska B, et al. (2021) The Differential Effect of Cannabidiol on the Composition and Physicochemical Properties of Keratinocyte and Fibroblast Membranes from Psoriatic Patients and Healthy People. Membranes (Basel). 4;11(2):111. doi: 10.3390/membranes11020111. PMID: 33557204.
Acesso: link
Maghfour J, et al. An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin. J Drugs Dermatol. 2020; 19(12):1204-1208. doi: 10.36849/JDD.2020.5464.
Acesso: link
Friedman AJ, et al. Topical Cannabinoids for the Management of Psoriasis Vulgaris: Report of a Case and Review of the Literature. J Drugs Dermatol. 2020; 19(8):795. doi: 10.36849/JDD.2020.5229.
Acesso: link
Maghfour J, et al. Tolerability Profile of Topical Cannabidiol and Palmitoylethanolamide: A Compilation of Single-Center Randomized Evaluator-Blinded Clinical and In Vitro Studies in Normal Skin. Clin Exp Dermatol. 2021. doi: 10.1111/ced.14749.
Acesso: link
Pandey S, et al. Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy. Complement Ther Med. 2020;48:102242. doi:10.1016/j.ctim.2019.102242
Acesso: link
Naftali , T., et al. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1376-1381. doi: 10.1097/MEG.0000000000001565.
Acesso: link
Kienzl M, et al. Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clin Transl Gastroenterol. 2020 Jan;11(1):e00120. doi: 10.14309/ctg.0000000000000120.
Acesso: link
Naftali , T. An overview of cannabis based treatment in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020 Apr;14(4):253-257. doi: 10.1080/17474124.2020.1740590. Epub 2020 Mar 12.
Acesso: link
Maselli , D., Camilleri , M. Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases. Clin Gastroenter
Acesso: link
Cocetta V, et al. Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress. Front Pharmacol. 2021; 12:641210. doi: 10.3389/fphar.2021.641210.
Acesso: link
Martínez V, et al. Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals? Int J Mol Sci. 2020; 21(9):3067. doi: 10.3390/ijms21093067.
Acesso: link
Naftali T. An overview of cannabis based treatment in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020; 14(4):253-257. doi: 10.1080/17474124.2020.1740590.
Acesso: link
Bains S, Mukhdomi T. Medicinal Cannabis For Treatment Of Chronic Pain. 2022 Jan 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 34662076.
Acesso: link
Xu DH, et al. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2019
Acesso: link
Pinsger M, et al. Benefits of an addon treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized controlled trial. Wien Klin Wochenschr 2006; 118(11–12):327–35
Acesso: link
Nitecka−Buchta A, et al. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double−Blind Trial. J Clin Med. 2019 Nov 6;8(11).
Acesso: link
Maher DP, et al. Cannabis for the Treatment of Chronic Pain in the Era of an Opioid Epidemic: A Symposium-Based Review of Sociomedical Science. Pain Med. 2017 Jul 13. doi: 10.1093/pm/pnx143.
Acesso: link
Häuser W, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018 Oct;22(9):1547-1564. doi: 10.1002/ejp.1297.
Acesso: link
Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia V1. 2017.
Acesso: link
Caterina MJ, et al. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999; 398:436–441.
Acesso: link
Sihota A, et al., (2020) Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract. 28:e13871. doi: 10.1111/ijcp.13871. Epub ahead of print. PMID: 33249713.
Acesso: link
Anthony, A.T., et al. (2020). Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review. Cureus. 14;12(9):e10436. doi: 10.7759/cureus.10436. PMID: 33072446; PMCID: PMC7557112.
Acesso: link
Narouze, S.(2020) Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians. Regional Anesthesia & Pain Medicine Published Online First: doi:10.1136/rapm-2020-102114.
Acesso: link
Chang Y, et al. (2021) Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations. Pain Res Manag. 4;2021:8857948. doi: 10.1155/2021/8857948. PMID: 33613794; PMCID: PMC7878090.
Acesso: link
Waissengrin B, et al. (2021) Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis. Ther Adv Med Oncol. 9;13:1758835921990203. doi: 10.1177/1758835921990203. PMID: 33613702; PMCID: PMC7876573.
Acesso: link
Urits I, et al. Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020; 34(3):463-477. doi: 10.1016/j.bpa.2020.06.004.
Acesso: link
Dykukha I, et al. Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. Pain Med. 2021; 22(4):861-874. doi: 10.1093/pm/pnab050.
Acesso: link
Strzelczyk A, Schubert-Bast S. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. CNS Drugs. 2022 Feb 14. doi: 10.1007/s40263-022-00898-1.
Acesso: link
Mazurkiewicz-Bełdzińska M, Zawadzka M. Use of cannabidiol in the treatment of epilepsy. Neurol Neurochir Pol. 2022;56(1):14-20. doi: 10.5603/PJNNS.a2022.0020.
Acesso: link
García-Peñas JJ, et al. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts’ recommendations for its use in clinical practice in Spain. Rev Neurol. 2021 Sep 10;73(S01):S1-S8. English, Spanish. doi: 10.33588/rn.73S01.2021250.
Acesso: link
Szaflarski JP, et al. (2018). Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy and behavior, 87, 131-136.
Acesso: link
Suraev A, et al. (2018). Composition and use of cannabis extracts for childhood epilepsy in the australian community. Scientific Reports, 8, 10154.
Acesso: link
Sun FJ, et al (2013). Increased expression of TRPV1 in the cortex and hippocampus from patients with mesial temporal lobe epilepsy. J. Mol. Neurosci. 49:182–193.
Acesso: link
Senn L, et al. Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy. Pharmaceuticals (Basel, Switzerland) 2020; 13(8):174.
Acesso: link
Rosenberg EC, et al. Quality of life of childhood epilepsy on pediatric enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia 2017; 58(8), 96-100.
Acesso: link
Reddy DS & Golub VM. The pharmacological basis of cannabis therapy for epilepsy. The journal of pharmacology and experimental therapeutics 2016; 357:45-55.
Acesso: link
O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. 2017 May;70(Pt B):341-348. doi: 10.1016/j.yebeh.2016.11.012.Epub 2017 Feb 8.
Acesso: link
Kaplan JS, et al (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. USA. 114:11229–11234.
Acesso: link
Devinsky O, et al. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol 2016; 15:270–278.
Acesso: link
Cunha JM, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21:175−185, 1980.
Acesso: link
American Academy of Neurology. Artisanal CBD not as effective as pharmaceutical CBD for reducing seizures. ScienceDaily 2020.
Acesso: link
Devinsky, O. et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. Massachusetts Medical Society. 2017; 376(21), pp. 2011–2020. doi: 10.1056/NEJMoa1611618.
Acesso: link
Gloss, D. and Vickrey, B. (2014) ‘Cannabinoids for epilepsy’, Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, (3). doi: 10.1002/14651858.CD009270.pub3.
Acesso: link
Alessandra Morano , A., et al. Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects. Neuropsychiatr Dis Treat. 2020 Feb 7;16:381-396. doi: 10.2147/NDT.S203782. eCollection 2020.
Acesso: link
Franco , V., Perucca , E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs. 2019 Sep;79(13):1435-1454. doi: 10.1007/s40265-019-01171-4.
Acesso: link
Doyle , A., Harvey , J. Cannabis and Epilepsy. J Dual Diagn. Jan-Mar 2020;16(1):75-82. doi: 10.1080/15504263.2019.1645372. Epub 2019 Aug 6.
Acesso: link
Silva GD, et al. Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps. Front Neurol. 2020 Oct 19;11:531939. doi: 10.3389/fneur.2020.531939. PMID: 33192966; PMCID: PMC7604476.
Acesso: link
Cáceres Guido P, et al. Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy. Epilepsia. 2020; 00:1–6.
Acesso: link
Wang, G.S., et al. (2020) Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. Clin Pharmacokinet 59, 1005–1012.
Acesso: link
Nicotera AG, et al. Epileptic Phenotype and Cannabidiol Efficacy in a Williams-Beuren Syndrome Patient With Atypical Deletion: A Case Report. Front Neurol. 2021; 12:659543. doi: 10.3389/fneur.2021.659543.
Acesso: link
Farrelly AM, et al. Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances. Int J Environ Res Public Health. 2021; 18(8):3993. doi: 10.3390/ijerph18083993.
Acesso: link
Gaston TE, et al. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy Behav. 2021; 117:107862. doi: 10.1016/j.yebeh.2021.107862.
Acesso: link
Lochte BC, et al. The Use of Cannabis for Headache Disorders. Cannabis Cannabinoid Res. 2017; 2(1):61-71. doi: 10.1089/can.2016.0033.
Acesso: link
Förderreuther S. Cannabis in headache treatment. MMW Fortschr Med 2018; 160(1):70-71. doi: 10.1007/s15006-018-0329-z.
Acesso: link
Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache. 2018 Jul;58(7):1139-1186. doi: 10.1111/head.13345.
Acesso: link
Baron EP, et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018 May 24;19(1):37. doi: 10.1186/s10194-018-0862-2.
Acesso: link
Cuttler C, et al. Craft RM. Short- and Long-Term Effects of Cannabis on Headache and Migraine. J Pain. 2019 Nov 9. pii: S1526-5900(19)30848-X. doi: 10.1016/j.jpain.2019.11.001. [Epub ahead of print]
Acesso: link
Leimuranta P, et al. Emerging Role of (Endo)Cannabinoids in Migraine. Front Pharmacol. 2018 Apr 24;9:420. doi: 10.3389/fphar.2018.00420. eCollection 2018.
Acesso: link
Aviram J., et al. Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study. Brain Sci . 2020 Jun; 10(6): 360. doi: 10.3390/brainsci1006036
Acesso: link
Mechtler, L.L., et al. (2021). Cannabis and Migraine: It’s Complicated. Curr Pain Headache Rep. 2021 Feb 25;25(3):16. doi: 10.1007/s11916-020-00931-2. PMID: 33630181.
Acesso: link
Giacoppo S, Mazzon E. Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? Neural Regen Res. 2016 Dec;11(12):1896-1899. doi: 10.4103/1673-5374.197125.
Acesso: link
Kim K, et al. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006 Aug 7;542(1-3):100-5.
Acesso: link
Shoemaker JL, et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007 Apr;101(1):87-98.
Acesso: link
Lim K, See YM, Lee J.A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clin Psychopharmacol Neurosci. 2017 Nov 30;15(4):301-312. doi: 10.9758/cpn.2017.15.4.301.
Acesso: link
Iskedjian, M. et al. Meta-analysis of cannabis-based treatments for neuropathic and multiple sclerosis-related pain, Current Medical Research and Opinion. 2017; 23(1), pp. 17–24. doi: 10.1185/030079906X158066.
Acesso: link
Fu, X. et al. (2018) ‘A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis’, Clinical Rehabilitation, 32(6), pp. 713–721. doi: 10.1177/0269215517745348.
Acesso: link
da Rovare, V. P. et al. (2017) ‘Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials’, Complementary Therapies in Medicine, 34, pp. 170–185. doi: 10.1016/j.ctim.2017.08.010.
Acesso: link
Wade, D. T. et al. (2010) ‘Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis’, Multiple Sclerosis Journal. SAGE PublicationsSage UK: London, England, 16(6), pp. 707–714. doi: 10.1177/1352458510367462.
Acesso: link
Yadav, V. et al. (2014) ‘Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology’, Neurology, 82(12), pp. 1083–1092. doi: 10.1212/WNL.0000000000000250.
Acesso: link
Youssef, N. A. et al. (2017) ‘Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and metanalysis’, BJU International, 119(4), pp. 515–521. doi:10.1111/bju.13759.
Acesso: link
Xu, D.H., et al. (2019) Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. Dec 1. doi: 10.2174/1389201020666191202111534.
Acesso: link
Furgiuele A, et al. Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review. J Neuroimmune Pharmacol. 2021; 16(2):251-269. doi: 10.1007/s11481-021-09982-7.
Acesso: link
Kim-Fine S, et al. Cannabinoids and bladder symptoms in multiple sclerosis. Mult Scler Relat Disord. 2021; 54:103105. doi: 10.1016/j.msard.2021.103105.
Acesso: link
Manera C, Bertini S. Cannabinoid-Based Medicines and Multiple Sclerosis. Adv Exp Med Biol. 2021;1264:111-129. doi: 10.1007/978-3-030-57369-0_8.
Acesso: link
Virgilio E, et al. Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1. Eur J Case Rep Intern Med. 2021; 8(5):002424. doi: 10.12890/2021_002424.
Acesso: link
Jones É, Vlachou S. A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules. 2020; 25(21):4930. doi: 10.3390/molecules25214930.
Acesso: link
Booz GW. Cannabidiol as na emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011; 1;51(5):1054-61
Acesso: link
Bustein S. Cannabidiol and its analogs: A review of their effects on inflammation. Bioorganic & Medicinal Chemistry 2015; 23(7):1377-85.
Acesso: link
Elkington LJ, et al. Inflammation and immune function: Can antioxidants help the endurance athlete? Antioxidants in Sport Nutrition. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 11.
Acesso: link
Naik H, Trojian TH. Therapeutic Potential for Cannabinoids in Sports Medicine: Current Literature Review. Curr Sports Med Rep. 2021; 20(7):345-350.
Acesso: link
Noreen N, et al. Is CBD a promising substance for new drug development? A review of its potential therapeutic applications. Crit Rev Eukaryot Gene Expr 2018; 28(1):73-86.
Acesso: link
Pellati F, et al Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry ans role against oxidative stress, inflammation and cancer. Biomed Res Int 2018: 1691428.
Acesso: link
Rojas-Valverde D. Potential role of cannabidiol on sports recovery: A narrative review. Front Physiol 2021; 12:722550. doi: 10.3389/fphys.2021.722550.
Acesso: link
Yassin M, et al. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol. 2019; 37 (Suppl. 116): S13-S20.
Acesso: link
Skrabek RQ, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008; 9(2):164–73
Acesso: link
Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2008; 29:192– 200
Acesso: link
Malfait AM, et al. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000; 97:9561–6
Acesso: link
Lee MC, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. 2013; 154:124–34
Acesso: link
Hillard CJ, et al. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience. 2012; 204:207–29
Acesso: link
Fitzcharles MA, et al. Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2016; 68(5):681-8.
Acesso: link
Clauw DJ. Fibromyalgia: A Clinical Review. JAMA 2014; 311(15):1547–55.
Acesso: link
Walitt, B. et al. (2016) ‘Cannabinoids for fibromyalgia (Review)’, Cochrane Database of Systematic Reviews, (7), pp. 1–29. doi: 10.1002/14651858.CD011694.pub2.www.cochranelibrary.com.
Acesso: link
Walitt, B. et al. (2016) ‘Cannabinoids for fibromyalgia (Review)’, Cochrane Database of Systematic Reviews, (7), pp. 1–29. doi: 10.1002/14651858.CD011694.pub2.www.cochranelibrary.com.
Acesso: link
Mazza M. Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series. J Cannabis Res. 2021 Feb 17;3(1):4. doi: 10.1186/s42238-021-00060-6. PMID: 33597032; PMCID: PMC7890993.
Acesso: link
Chaves C, et al. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pain Med. 2020; 21(10):2212-2218. doi: 10.1093/pm/pnaa303.
Acesso: link
Mazza M. Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series. J Cannabis Res. 2021; 3(1):4. doi: 10.1186/s42238-021-00060-6. PMID: 33597032; PMCID: PMC7890993.
Acesso: link
Hartmann A, et al. Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2019 May 2;94:109637. doi: 10.1016/j.pnpbp.2019.109637.
Acesso: link
Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011; 36:1219–1226. doi: 10.1038/npp.2011.6.
Acesso: link
van der Flier, F.E., et al. (2019). Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. BMC Psychiatry. 13;19(1):69. doi: 10.1186/s12888-019-2022-x.
Acesso: link
Anderson LL, et al (2019). Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 60:2224–2234.
Acesso: link
Balachandran P, et al. Cannabidiol interactions with medications, illicit substances and alcohol: a comprehensive review. J Gen Inter Med 2021; 36:2074-2084.
Acesso: link
Blaszczyk B, et al. A viewpoint on rational and irrational fixed−drug combinations. Exp Rev Clin Pharmacol. 2018
Acesso: link
Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer CBD use. J Clin Med 2019; 8(7):989.
Acesso: link
Bruce D, et al. Preferences for medical marijuana over prescription medications among persons living with chronic conditions: alternative, complementary, and tapering uses. J Altern Complement Med. 2018
Acesso: link
Cox EJ, et al. A marijuana−drug interaction primer: precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther. 2019
Acesso: link
Foster BC, et al. Cannabis and Cannabinoids: Kinetics and Interactions. Am J Med. 2019
Acesso: link
Gaston TE, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017
Acesso: link
Geffrey AL, et al. Drug−drug interaction between clozabam and cannabadiol in children with refractory epilepsy. Epilepsia. 2015
Acesso: link
Gunning B, et al (2021). Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta neurologica Scandinavica, 143(2), 154–163.
Acesso: link
Holland ML, et al. Interactions of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008
Acesso: link
Holland ML, et al. The effects of cannabinoids on P−glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol. 2006
Acesso: link
Ifland K, Grotenherman F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis and Cannabinoid Res. 2017.
Acesso: link
Jiang R, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013
Acesso: link
Karniol I.G., et al (1974). Cannabidiol interferes with the effects of delta 9 – tetrahydrocannabinol in man. Eur. J. Pharm. 28:172–177. doi: 10.1016/0014-2999(74)90129-0.
Acesso: link
Kocis PT, Vrana KE. Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions. Med Cannabis Cannabinoids 2020; 3:61-73.
Acesso: link
Manini AF, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015
Acesso: link
Miziak B, et al. Drug-drug interactions between antiepileptics and cannabinoids. Expert Opinion on Drug Metabolism & Toxicology. 2019
Acesso: link
Opitz BJ, et al. The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer. J Pharm Pract 2020; 33(4):506-512. doi: 10.1177/0897190019828920.
Acesso: link
Santana, T. A. et al. (2015) ‘Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting’, Supportive Care in Cancer. Springer Berlin Heidelberg, 23(1), pp. 213– 222. doi: 10.1007/s00520-014-2392-z.
Acesso: link
Smith, L. A. et al. (2015) ‘Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy’, Cochrane Database of Systematic Reviews, (11), p. CD009464. doi: 10.1002/14651858.CD009464.pub2.
Acesso: link
Serafimovska T, et al. Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy. Folia Med (Plovdiv). 2020; 62(4):668-678. doi: 10.3897/folmed.62.e51478.
Acesso: link
Grimison P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020; 31(11):1553-1560. doi: 10.1016/j.annonc.2020.07.020.
Acesso: link
Cavalheiro EKFF, et al. Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target. Cannabis Cannabinoid Res 2021. doi: 10.1089/can.2021.0016.
Acesso: link
Skinner, C. M., et al. (2020) Potential Probiotic or Trigger of Gut Inflammation – The Janus-Faced Nature of Cannabidiol-Rich Cannabis Extract, Journal of Dietary Supplements, 17:5, 543-560, DOI:
Acesso: link
Bielawiec, P., et al. (2020). Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol. Front Endocrinol (Lausanne) . 11:114. Published 2020 Mar 4. doi:10.3389/fendo.2020.00114
Acesso: link
Fellous, T., et al. (2020). Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. Biochem Pharmacol . 175: 113859. doi:10.1016/j.bcp.2020.113859
Acesso: link
Opyd, P.M., et al. (2020). Dietary Hemp Seeds More Effectively Attenuate Disorders in Genetically Obese Rats than Their Lipid Fraction. J Nutr . 2020;150(6):1425-1433. doi:10.1093/jn/nxaa081
Acesso: link
Ramlugon, S, et al. (2018). Time-dependent effect of phytocannabinoid treatments in fat cells. Phytother Res . 32(6):1080-1089. doi:10.1002/ptr.6047
Acesso: link
Rakotoarivelo V, et al. Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism. Cells. 2021; 10(6):1279. doi: 10.3390/cells10061279.
Acesso: link
Bodine M, Kemp AK. Medical Cannabis Use In Oncology. 2022 Jan 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 34283433.
Acesso: link
Melén CM, et al. Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
Acesso: link
O’Brien K. Cannabidiol (CBD) in Cancer Management. Cancers (Basel). 2022 Feb 10;14(4):885. doi: 10.3390/cancers14040885.
Acesso: link
Nahler G. Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics. Pharmaceut Med. 2022 Mar 4. doi: 10.1007/s40290-022-00420-4.
Acesso: link
Lukhele, S. T. & Motadi, L. R. (2016). Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complementary and Alternative Medicine, 16(1), 335.
Acesso: link
Bacil, E.D., et al. (2015). Atividade física e maturação biológica: uma revisão sistemática [Physical activity and biological maturation: a systematic review]. Rev Paul Pediatr. 2015;33(1):114-121. doi:10.1016/j.rpped.2014.11.003.
Acesso: link
VanDolah, H. J., et al. Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clinic Proceedings, Volume 94, Issue 9, 1840 – 1851
Acesso: link
Kisková, T., et al. (2019). Mungenast F, Suváková M, Jäger W, Thalhammer T. Future Aspects for Cannabinoids in Breast Cancer Therapy. Int J Mol Sci . 20(7):1673.
Acesso: link
Opitz, B.J., et al. (2019) The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer. J Pharm Pract .
Acesso: link
Afrin, F., et al. (2020) Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer. Cancers (Basel) . 12(4):1033. Published 2020 Apr 23. doi:10.3390/cancers12041033
Acesso: link
Kleckner , A., et al. (2019). Opportunities for cannabis in supportive care in cancer. Ther Adv Med Oncol . 11: 1758835919866362.
Acesso: link
Lal, S., et al. (2020) Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities. Pharmacol Res. 2020 Nov 24;163:105302. doi: 10.1016/j.phrs.2020.105302. Epub ahead of print. PMID: 33246167.
Acesso: link
Śledziński, P., et al. (2020) Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases. Int J Mol Sci. Dec 29;22(1):E263. doi: 10.3390/ijms22010263. PMID: 33383838.
Acesso: link
Wang F, Multhoff G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules. 2021; 11(4):582. doi: 10.3390/biom11040582.
Acesso: link
Irrera N, et al. Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies. Molecules. 2021; 26(13):3866. doi: 10.3390/molecules26133866.
Acesso: link
Ożarowski M, et al. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. Int J Mol Sci. 2021; 22(9):4294. doi: 10.3390/ijms22094294.
Acesso: link
Zuardi AW, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009; 23: 979−983.
Acesso: link
Morera−Herreras T, et al. Endocannabinoid modulation of dopaminergic motor circuits − Frontiers in Pharmacology | Neuropharmacology June 2012 ; Volume 3 : 110 − 2
Acesso: link
Linares IM, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019 Jan-Feb;41(1):9-14.
Acesso: link
Libzon S, et al. Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. J Child Neurol. 2018 Aug;33(9):565-571. doi: 10.1177/0883073818773028.
Acesso: link
Iuvone T, et al. Cannabidiol: A Promising Drug for Neurodegenerative Disorders? − CNS Neuroscience & Therapeutics 2009; 15 (2009) 65−75.
Acesso: link
Crippa JAS, et al. Is cannabidiol the ideal drug to treat non−motor Parkinson’s disease symptoms? − Eur Arch of Psych and Clin Neurosc 2019; 269 (1):121−133
Acesso: link
Chagas MHN et al. Cannabidiol can improve complex sleep−related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. Journal of Clinical Pharmacy and Therapeutics 2014; 39:564−566
Acesso: link
de Faria, S.M., et al. (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 7:269881119895536. doi: 10.1177/0269881119895536.
Acesso: link
Peres, F.F., et al. (2018). Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? Front Pharmacol. 11; 9:482. doi: 10.3389/fphar.2018.00482. eCollection 2018.
Acesso: link
Koppel BS (2015). Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. Neurotherapeutics. 12(4):788-92. doi: 10.1007/s13311-015-0376-4. Review.
Acesso: link
C Ferreira-Junior , N., et al. (2020). Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Braz J Psychiatry. 42(2):218-224. doi: 10.1590/1516-4446-2019-0460. Epub 2019 Jul 15.
Acesso: link
Junior , N., et al. (2020). Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and L-DOPA-Induced Dyskinesia. Neurotox Res. 2020 Jan;37(1):12-29. doi: 10.1007/s12640-019-00109-8.
Acesso: link
Patricio F, et al. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Front Pharmacol. 2020; 11:595635. doi: 10.3389/fphar.2020.595635.
Acesso: link
Cooray R, et al. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Mol Neurobiol. 2020;57(11):4878-4890. doi: 10.1007/s12035-020-02054-6.
Acesso: link
MacCalluma, C. A., Russob, E. B. − Practical considerations in medical cannabis administration and dosing − European Journal of Internal Medicine 2018; 49: 12−19.
Acesso: link
Millar, S. A., Stone, N. L., Bellman Z.D., Yates, A. S., England, T.J., O’Sullivan, S. E. − A systematic review of cannabidiol dosing in clinical populations. − Br J Clin Pharmacol. 2019; 85:1888−1900.
Acesso: link
VanDolah HJ, Bauer BA, Mauck KF. Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019 Sep;94(9):1840−51. Review.
Acesso: link
Szejko N, Saramak K, Lombroso A, Müller-Vahl K. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurol Neurochir Pol. 2022;56(1):28-38. doi: 10.5603/PJNNS.a2021.0081.
Acesso: link
Schwittay MA, Steinbrecher A, Lobsien E. Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray. Tremor Other Hyperkinet Mov (N Y). 2021 Aug 6;11:33. doi: 10.5334/tohm.613.
Acesso: link
Müller-Vahl KR. (2013). Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 27(1):119-24. doi: 10.3233/BEN-120276. Review.
Acesso: link
Artukoglu, B.B., Bloch, M.H. (2019) The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. CNS Drugs. 33(5):417-430. doi: 10.1007/s40263-019-00627-1.
Acesso: link
Thaler, A., et al. (2019). Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism Relat Disord. 2019 Apr; 61:211-213. doi: 10.1016/j.parkreldis.2018.10.004.
Acesso: link
Pichler EM, et al. (2019) Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report. Int J Psychiatry Med. 54(2):150-156. doi: 10.1177/0091217418791455. Epub 2018 Jul 30.
Acesso: link
Jakubovski E, Müller-Vahl K (2017). Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. Int J Mol Sci. 10;18(8). pii: E1739. doi: 10.3390/ijms18081739.
Acesso: link
Abi-Jaoude E, et al. (2017) Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome. J Neuropsychiatry Clin Neurosci. 29(4):391-400. doi: 10.1176/appi.neuropsych.16110310.
Acesso: link
Khan R, et al. The therapeutic role of Cannabidiol in mental health: a systematic review. J Cannabis Res. 2020; 2(1):2. doi: 10.1186/s42238-019-0012-y.
Acesso: link
Bhattacharyya S, et al. Opposite effects of delta−9−tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacol 2010; 35:764−774.
Acesso: link
Boggs DL, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo−controlled trial. Psychopharmacol (Berl) 2018; 235: 923−1932, 2018.
Acesso: link
Crippa JAS, et al. Therapeutical use of the cannabinoids in psychiatry. Revista Brasileira de Psiquiatria 2010; 32(1): 56-66.
Acesso: link
Davies C. e Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol. 9: 1−16, 2019.
Acesso: link
De Marchi N., et al. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 2:5
Acesso: link
Fernandez−Espejo E, et al. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009; 4:531Y549.
Acesso: link
Ferretjans R, et al. Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophr Res. 156(2− 3):254−260, 2014.
Acesso: link
Giuffrida A., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29(11):2108−14.
Acesso: link
Gururajan A. e Malone D.T. Does cannabidiol have a role in the treatment of schizophrenia? SchizophreniaResearch, Melbourne, p. 1−10, 2016.
Acesso: link
Koethe D, et al. Familial abnormalities of endocannabinoid signaling in schizophrenia. World J Biol Psychiatry 2018; 22:1−9, 2018.
Acesso: link
Leweke FM, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2:e94.
Acesso: link
Leweke FM, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 10(8):1665−9, 1999.
Acesso: link
Leweke FM et al. Therapeutic Potential of Cannabinoids in Psychosis. Biol Psychiatry 2016; 79: 604–612.
Acesso: link
McGuire P., et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 1;175:225−231, 2018.
Acesso: link
Minichino A., et al. Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta−analysis. JAMA Psychiatry. June 5, 2019.
Acesso: link
Pedrazzi J.F.C., et al. Perfil antipsicótico do canabidiol. RevistaMedicina, Ribeirão Preto−SP, v. 47, n. 2, p. 112−119, 2014..
Acesso: link
Reuter AR, et al. Association of anandamide with altered binocular depth inversion illusion in schizophrenia. The World Journal of Biological Psychiatry 2017; 18:483−488.
Acesso: link
Volk D.W. e Lewis D.A. The role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia. Biol Psychiatry 2016; 79(7):595−603.
Acesso: link
Wong D.F., et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010; 4:1505Y1513.
Acesso: link
Zuardi AW, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharma Des 2012; 18:5131−5140.
Acesso: link
Zuardi AW, et al. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56:485−486.
Acesso: link
Zuardi AW, et al. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacol 1991; 104:260−264.
Acesso: link
Cooper, R.E., et al. (2017) Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 27(8):795-808.
Acesso pago: link
Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019; 6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28. Erratum in: Lancet Psychiatry. 2020 Jan;7(1):e3.
Acesso: link
Melas PA, et al (2021). Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. Int J Mol Sci. Feb 13;22(4):1863. doi: 10.3390/ijms22041863. PMID: 33668469; PMCID: PMC7917759.
Acesso: link
Lucatch AM, Coles AS1, Hill KP, George TP. Cannabis and Mood Disorders. Curr Addict Rep. 2018 Sep;5(3):336-345. doi: 10.1007/s40429-018-0214-y. Epub 2018 May
Acesso: link
Pinto JV, et al. (2019) Cannabidiol as a Treatment for Mood Disorders: A Systematic Review. 13:706743719895195. doi: 10.1177/0706743719895195. [Epub ahead of print]
Acesso pago: link
Kayser , R., et al. (2020) Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.Depress Anxiety. 2020 Aug;37(8):801-811. doi: 10.1002/da.23032. Epub 2020 May 7.
Acesso: link
Stanciu CN, et al. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatr Serv. 2021; 72(4):429-436. doi: 10.1176/appi.ps.202000189.
Acesso: link
Stasiłowicz A, et al (2021). Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment. International journal of molecular sciences, 22(2), 778.
Acesso: link
Sarris J, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020 Jan 16;20(1):24. doi: 10.1186/s12888-019-2409-8.
Acesso: link
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid−terpenoid entourage effects. Br J Pharmacol 2011; 163:1344−64.
Acesso: link
Pertwee RG, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2. Pharmacol Rev 2010; 62:588- 631. doi: 10.1124/pr.110.003004.
Acesso: link
Pacher P, et al. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58, 389-462.
Acesso: link
Munro S, et al (1993). Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:61–65.
Acesso: link
Mechoulam R., et al. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 15:757−764, 2014.
Acesso: link
Lu HC, Mackie K (2016). An Introduction to the Endogenous Cannabinoid System. Biol. Psychiatry. 79:516–525.
Acesso: link
Lowe H, et al. Potential of Cannabidiol for the Treatment of Viral Hepatitis. Pharmacognosy Research. 2017; 9(1):116−8.
Acesso: link
Katona I, Freund TF (2012). Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 35:529–558.
Acesso: link
Kathmann M, et al (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch. Pharmacol. 372:354–361.
Acesso: link
Crippa JA, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29:417–426. doi: 10.1038/sj.npp.1300340.
Acesso: link
Castaneto MS, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014; 144:12−41.
Acesso: link
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012; 367(1607):3364-78. doi: 10.1098/rstb.2011.0389.
Acesso: link
Bakas T, et al. The direct actions of cannabidiol and 2-arachidonoyl glycerol on GABA-A receptors. Pharmacol Res 2017; 119:358– 370.
Acesso: link
Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2(6):241−254.
Acesso: link
Andre CM, et al (2016). Cannabis sativa: The Plant of the Thousand and One Molecules. Frontiers in plant science, 7, 19.
Acesso: link
Alexandre J. et al. Synthetic cannabinoids and their impact on neurodevelopmental processes. Addiction Biology 2020; 25(2):e12824. doi: 10.1111/adb.12824.
Acesso: link
National Academy of Sciences Entineering, and M. (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press. doi: 10.17226/24625.
Acesso: link
Phillips, T. J. C. et al. (2010) ‘Pharmacological Treatment of Painful HIV-Associated Sensory Neuropathy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials’, PLoS ONE. Edited by N. P. Pai, 5(12), p. e14433. doi: 10.1371/journal.pone.0014433.
Acesso: link
Lucas CJ, et al. (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. doi: 10.1111/bcp.13710.
Acesso: link
Crockett, J., et al. (2020). A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. doi: 10.1111/epi.16419.
Acesso: link
Whiting, P. F. et al. (2015) Cannabinoids for medical use: a systematic review and meta-analysis, JAMA, 313(24), p. 2456. doi: 10.1001/jama.2015.6358.
Acesso: link
Black N, et al. (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8.
Acesso: link
Singer L, et al. (2020) The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children. Curr Opin Pediatr. 32(1):198-205.
Acesso: link
Alves , P., et al (2020). Cannabis sativa: Much more beyond Δ 9-tetrahydrocannabinol. Pharmacol Res. 2020 Jul;157:104822. doi: 10.1016/j.phrs.2020.104822.
Acesso: link
Bridget H Highe t, B., et al. (2020). Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population. Am J Hosp Palliat Care. 37(8):589-593. doi: 10.1177/1049909119900378.
Acesso: link
Karan Mathur , K., et al. (2020) Cannabidiol (CBD) Consumption and Perceived Impact on Extrahepatic Symptoms in Patients with Autoimmune Hepatitis.Dig Dis Sci. 65(1):322-328. doi: 10.1007/s10620-019-05756-7.
Acesso: link
Oberbarnscheidt , T., Miller , N. (2020) The Impact of Cannabidiol on Psychiatric and Medical Conditions. J Clin Med Res. 12(7):393-403. doi: 10.14740/jocmr4159. Epub 2020 Jun 25.
Acesso: link
Černe K (2020). Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol. Arh Hig Rada Toksikol. 1;71(1):1-11. doi: 10.2478/aiht-2020-71-3301. PMID: 32597140.
Acesso: link
Taylor L, et al (2020) Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav. 104(Pt A):106938. doi: 10.1016/j.yebeh.2020.106938. Epub 2020 Feb 7. PMID: 32036242.
Acesso: link
Patel AD (2021). Cannabinoids in Neurologic Illnesses. Neurol Clin. 39(1):231-241. doi: 10.1016/j.ncl.2020.09.012. Epub 2020 Nov 7. PMID: 33223086.
Acesso: link
Vázquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. Biomed Res Int. 2020 Aug 13;2020:3902740. doi: 10.1155/2020/3902740. PMID: 32855964; PMCID: PMC7443220.
Acesso: link
Bansal S, et al. (2020) Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. Drug Metab Dispos. 48(10):1008-1017. doi: 10.1124/dmd.120.000073. Epub 2020 Jun 25. PMID: 32587099; PMCID: PMC7543485.
Acesso: link
Gottschling S, et al. (2020) Safety Considerations in Cannabinoid-Based Medicine. Int J Gen Med. 1;13:1317-1333. doi: 10.2147/IJGM.S275049. PMID: 33299341; PMCID: PMC7720894.
Acesso: link
Cohen K, et al. (2019) Modulatory effects of cannabinoids on brain neurotransmission. Eur J Neurosci. 2019 Aug;50(3):2322-2345. doi: 10.1111/ejn.14407.
Acesso: link
Berk K, et al (2021). Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment. J Clin Med. 20;10(3):393. doi: 10.3390/jcm10030393. PMID: 33498537; PMCID: PMC7864168.
Acesso: link
Sholler DJ, et al. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. J Anal Toxicol. 2021 :bkab059. doi: 10.1093/jat/bkab059.
Acesso: link
Sampson PB. Phytocannabinoid Pharmacology: Medicinal Properties of Cannabis sativa Constituents Aside from the “Big Two”. J Nat Prod. 2021; 84(1):142-160. doi: 10.1021/acs.jnatprod.0c00965.
Acesso: link
